Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Berkowitz

Showing results (391-400 of 497) with videos related to

Pageof 50
Sort By:
Cardiovascular Research|April 15, 2020
Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery diseaseYan Liang, Jun Zhu, Lisheng Liu, et al.
European Journal of Preventive Cardiology|October 17, 2019
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trialThomas Vanassche, Peter Verhamme, Sonia S Anand, et al.
Journal of the American College of Cardiology|August 21, 2024
Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity RevascularizationMario Enrico Canonico, Cecilia C Low Wang, Judith Hsia, et al.
The Journal of Invasive Cardiology|November 11, 2003
The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main resultsKenneth W Mahaffey, Bruce E Lewis, Nancy M Wildermann, et al.
Stroke|September 19, 2019
Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS TrialGeorge Ntaios, Lesly A Pearce, Elena Meseguer, et al.
Vascular Medicine (London, England)|April 25, 2022
Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PADShea E Hogan, Mark R Nehler, Sonia Anand, et al.
Stroke|June 11, 2020
Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source: NAVIGATE-ESUS TrialRobert Mikulík, Jens Eckstein, Lesly A Pearce, et al.
The Lancet. Haematology|April 1, 2016
Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trialsMartin H Prins, Anthonie W A Lensing, Tim A Brighton, et al.
The American Journal of Cardiology|June 25, 2017
Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial)Jeffrey B Washam, Anne S Hellkamp, Yuliya Lokhnygina, et al.
American Heart Journal|September 7, 2016
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trialRohan Shah, Anne Hellkamp, Yuliya Lokhnygina, et al.
Pageof 50

Showing results (391-400 of 497) with videos related to

Sort By:
Pageof 50
Cardiovascular Research|April 15, 2020
Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery diseaseYan Liang, Jun Zhu, Lisheng Liu, et al.
European Journal of Preventive Cardiology|October 17, 2019
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trialThomas Vanassche, Peter Verhamme, Sonia S Anand, et al.
Journal of the American College of Cardiology|August 21, 2024
Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity RevascularizationMario Enrico Canonico, Cecilia C Low Wang, Judith Hsia, et al.
The Journal of Invasive Cardiology|November 11, 2003
The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main resultsKenneth W Mahaffey, Bruce E Lewis, Nancy M Wildermann, et al.
Stroke|September 19, 2019
Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS TrialGeorge Ntaios, Lesly A Pearce, Elena Meseguer, et al.
Vascular Medicine (London, England)|April 25, 2022
Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PADShea E Hogan, Mark R Nehler, Sonia Anand, et al.
Stroke|June 11, 2020
Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source: NAVIGATE-ESUS TrialRobert Mikulík, Jens Eckstein, Lesly A Pearce, et al.
The Lancet. Haematology|April 1, 2016
Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trialsMartin H Prins, Anthonie W A Lensing, Tim A Brighton, et al.
The American Journal of Cardiology|June 25, 2017
Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial)Jeffrey B Washam, Anne S Hellkamp, Yuliya Lokhnygina, et al.
American Heart Journal|September 7, 2016
Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trialRohan Shah, Anne Hellkamp, Yuliya Lokhnygina, et al.
Pageof 50